Secondary Investments

David de Weese joined Paul Capital in 1995 and leads global secondary transaction sourcing activities for the firm. Following fourteen years of management experience in Europe, Mr. de Weese served as President and CEO of biotechnology company, SigA Pharmaceuticals; California-based pharmaceutical company Cygnus Therapeutic Systems; and a Silicon Valley software company. Mr. de Weese received a B.A. from Stanford University, an M.B.A. from the Harvard Business School and attended law school at Stanford University.